Enhancing the NIDA Clinical Trials Network to Address Opioids


To expand NIH research to more communities in areas of the country that are severely impacted by the opioid crisis, the National Institutes of Health is expanding the National Drug Abuse Treatment Clinical Trials Network (CTN). The Network facilitates collaboration between government researchers, scientists at universities, and treatment providers in local communities with the aim of developing, testing, and implementing new addiction treatments. Through its work to date, the Network has contributed to broad-reaching changes in medical practice, including the development of the opioid use disorder (OUD) treatment medication buprenorphine.

The expansion effort will:

  • Strengthen the CTN’s capacity to conduct trials by adding new sites and new investigators;
  • Expand existing studies in the network, and initiate research with new investigators, in settings such as primary care and criminal justice, and new locations hard hit by the opioid crisis;
  • Facilitate the development and implementation of new studies to improve access to high-quality addiction treatment, including by facilitating delivery of OUD treatment in general medical settings;
  • Create new opportunities for clinical and research training.

Supporting NIH Institutes and Centers

National Institute on Drug Abuse (NIDA)


National Drug Abuse Treatment Clinical Trials Network (CTN)


Dr. Betty Tai

This page last reviewed on August 2, 2019